Comparison of quantitative measurements of 177Lu using SPECT/CT
Dosimetry in nuclear medicine therapy (molecular radiotherapy) is still in its infancy due to the complex problems associated with recovering activity distributions within patients over time. Recently, 177Lu has become popular for the treatment of neuroendocrine tumours by means of Peptide Receptor Radionuclide Therapy (PRRT).
Due to the medium range (1.2 mm) beta emissions this radionuclide is well suited for treatment of small tumours and due to its gamma emissions at 113 and 208 keV it is also well suited for imaging using planar or SPECT (Single Photon Emission Computer Tomography).
This paper presents the ability of three different SPECT/CT systems to determine accurate activity distributions from images of a relatively simple geometry (elliptical Jaszczak phantom) and gives indications of expected uncertainties associated with such measurements.
Download (PDF 900 KB)
Please note that the information will not be divulged to third parties, or used without your permission